Longevity Drugs: Do Metformin and Rapamycin Work?

If aging is a set of biological mechanisms, then in principle a drug could act on those mechanisms directly, slowing aging the way a statin lowers cholesterol. This is the frontier of longevity science and the source of both genuine research and enormous hype. This lesson separates the two.

Start with an essential ground truth: as of today, no drug is approved anywhere specifically to treat aging. Regulators do not yet recognize "aging" as a condition to prescribe against, so every candidate here is either approved for a different purpose and studied off-label for aging, or purely experimental. Nothing in this lesson is a recommendation to take anything; the goal is to understand what the evidence does and does not show.

The central challenge shadows everything: the mouse-to-human gap. Many compounds extend lifespan impressively in worms, flies, and mice. But most things that work in short-lived lab animals fail to show the same benefit in humans, whose biology is more complex and who live far too long to test easily. A slowing of aging is extraordinarily hard to prove in people, because you would have to follow them for decades.

So hold two ideas at once as we go: the science is real and genuinely promising, and the human evidence for actually slowing aging is, for every candidate, still limited or unproven. Both are true, and keeping them together is what separates informed understanding from either hype or dismissal.

The drug with the most impressive lifespan data in animals is rapamycin, and understanding it shows how a longevity drug is supposed to work by targeting a hallmark.

Rapamycin inhibits a cellular pathway called mTOR, a master nutrient sensor that tells cells whether to grow or to repair and recycle. When mTOR is active, cells grow; when it is dampened, cells shift toward maintenance, including the autophagy "recycling" from the first lesson. Rapamycin dials mTOR down, nudging cells from a growth mode toward a repair mode, acting directly on the deregulated-nutrient-sensing hallmark.

The animal evidence is genuinely striking. In rigorous experiments, including the National Institute on Aging's testing program, rapamycin has repeatedly extended lifespan in mice, even when started late in life. A 2025 meta-analysis spanning many studies and multiple species found that rapamycin's lifespan effect mirrors that of dietary restriction, one of the most reliable longevity interventions known.

But the human story is cautious. Rapamycin at the high, continuous doses used in transplant medicine suppresses the immune system, which is dangerous. The longevity hypothesis is that low, intermittent doses might capture benefits while avoiding that, and small human trials are exploring this, but there is no proof yet that it slows human aging. It remains experimental for longevity, used this way only in research or carefully supervised settings.

Rapamycin is the clearest case of the lesson's tension: the best animal evidence in the field, paired with real risks and still-unproven human benefit.

The most famous candidate is metformin, a cheap, decades-old diabetes drug taken safely by millions, which some researchers suspect has anti-aging effects as a side benefit.

The interest began with observations that diabetics taking metformin sometimes appeared to have lower rates of age-related diseases. Mechanistically, metformin affects metabolism and nutrient-sensing pathways in ways that plausibly touch several hallmarks. That plausibility, plus its safety and low cost, made it the obvious first candidate to test.

This inspired a landmark proposed study: TAME (Targeting Aging with Metformin), designed by researcher Nir Barzilai and the American Federation for Aging Research, aiming to enroll over 3,000 older adults. Its historic significance is less about metformin than about precedent: TAME is designed to be the first major trial to test a drug against aging itself as the target, rather than a single disease, which could open a regulatory path for future aging drugs. As of 2025 the effort is still working toward completion.

The evidence, though, is genuinely mixed. Metformin's benefits are clear in diabetics, but whether it slows aging in healthy people is unproven. Notably, the 2025 cross-species meta-analysis found that, unlike rapamycin, metformin did not reliably extend lifespan in the animal data. There is even evidence that metformin may blunt some of the benefits of exercise, which, given the last lesson, would be a serious trade-off.

Metformin's real importance right now is symbolic and scientific: it is the test case for whether "aging" can be treated as a medical target at all, more than it is a proven longevity drug.

A different and elegant strategy targets one specific hallmark: senolytics, drugs designed to selectively destroy the senescent "zombie cells" introduced in the first lesson.

Recall that senescent cells are damaged cells that stop dividing but refuse to die, and that they secrete inflammatory signals poisoning healthy neighbors and driving chronic inflammation. The senolytic idea is beautifully direct: if these cells cause harm by accumulating, selectively kill and clear them, and the tissue should improve. Unlike a drug you take constantly, senolytics could in principle be given intermittently, a "clear out the junk" treatment now and then.

The animal evidence is encouraging: clearing senescent cells in mice has improved multiple measures of health and function. In humans, the most studied combination is the cancer drug dasatinib paired with quercetin, a plant compound. Early, small human trials have shown reductions in markers of senescent cells in specific conditions such as idiopathic pulmonary fibrosis and diabetic kidney disease.

But the human evidence is still early-stage and disease-specific, not proof of general anti-aging benefit in healthy people. These are small trials on particular illnesses, and the leap to "take senolytics to age slower" is not yet supported.

Senolytics represent the appeal of precisely targeting a single well-understood hallmark. They are one of the more promising directions, but like everything in this lesson, they sit at the boundary where genuine, mechanism-driven research has not yet become proven human therapy.

No longevity topic is more heavily marketed than NAD boosters, supplements like NMN and NR, and they are the perfect case study in how mechanism gets ahead of evidence.

The reasoning starts sound. NAD+ is a molecule every cell needs for energy production and DNA repair, and its levels decline with age. The logic follows naturally: if NAD falls as we age, perhaps raising it with a supplement precursor could restore youthful function. Because the mechanism is real and easy to explain, it became a marketing sensation, sold widely as an anti-aging supplement.

Here is the gap. That NAD declines with age is well established. That taking NMN or NR meaningfully slows human aging is not. Supplements can raise NAD-related markers in the blood, but whether that translates into living longer or healthier in humans remains unproven, and human trials so far have not delivered the dramatic benefits the marketing implies.

This is the recurring trap of the supplement world: a true mechanism (NAD declines) is used to sell a product whose actual human benefit is unestablished. A plausible story is not evidence of an effect. The cautionary precedent is resveratrol, the red-wine compound that a decade ago was hyped as a longevity breakthrough on the strength of mechanism and animal hints, and then largely failed to show meaningful human anti-aging benefits.

The lesson is not that NAD research is worthless, it is legitimate science, but that "scientists found this molecule matters for aging" is very different from "this supplement will make you age slower," and the supplement industry systematically blurs the two.

A newer and different category deserves mention because it is reshaping the conversation: the GLP-1 receptor agonist drugs, originally developed for diabetes and now widely used for weight loss.

These drugs are not marketed as longevity drugs, and they do not target a hallmark of aging directly. But they matter to the field for a concrete reason: many age-related diseases, heart disease, type 2 diabetes, and others, are driven by metabolic dysfunction and excess body fat. By powerfully improving weight and metabolic health, GLP-1 drugs can reduce the burden of these conditions. Large trials have shown cardiovascular benefits in appropriate patients, meaning fewer heart attacks and strokes.

The longevity relevance is indirect but real. If a drug substantially reduces the diseases that shorten and worsen later life, it can extend healthspan even without acting on the fundamental aging clock. It attacks aging's consequences rather than its root mechanisms.

This reframes an important point. There are two different routes to a longer, healthier life through medicine: treating aging itself (rapamycin, senolytics, the hard and unproven path) and treating the specific diseases of aging better (GLP-1 drugs, statins, blood-pressure drugs, the established path). The second route has quietly delivered most of the real gains in healthy longevity so far.

GLP-1 drugs are a reminder that the biggest near-term wins in longevity may come not from exotic anti-aging compounds but from effectively managing the metabolic and cardiovascular problems that actually kill and disable people, an unglamorous truth that echoes the last lesson's message about the boring basics.

Pull the candidates together and a clear framework emerges for evaluating any longevity drug or supplement claim, which is the durable skill this lesson offers.

Notice the consistent pattern down the right column: the human anti-aging evidence is limited or unproven for every one. That is the honest state of the field, not pessimism but accuracy.

From this, a checklist for any claim you encounter:

• Animal or human? Impressive mouse results are a starting point, not a conclusion. Most fail to translate.
• Mechanism or outcome? "It affects a pathway involved in aging" is not "it makes people live longer." Demand the outcome, not just the story.
• Healthspan or a marker? Improving a blood biomarker is not the same as improving health or lifespan.
• Who benefits from the claim? Supplements are a large industry with strong incentives to overstate.

The balanced conclusion: this is legitimate, exciting science, and it is entirely possible that effective aging drugs will eventually be proven. But today, no pill has been shown to slow human aging, and the interventions with the best human evidence remain the lifestyle levers of the previous lesson. The rational stance is curiosity about the research paired with skepticism toward anything sold as a shortcut, and the final lesson turns to the tools that will actually settle these questions: how we measure biological aging.

Each leading candidate targets a mechanism of aging with real animal or mechanistic support, yet all share the same bottom line: human anti-aging benefit is still limited or unproven, so claims must be judged by outcome, not mechanism.